Curanex Pharmaceuticals (CURX)
Market Price (6/28/2026): $0.27 | Market Cap: $7.7 MilSector: Health Care | Industry: Biotechnology
Curanex Pharmaceuticals (CURX)
Market Price (6/28/2026): $0.27Market Cap: $7.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -48% | Weak multi-year price returns2Y Excs Rtn is -91%, 3Y Excs Rtn is -125% | Penny stockMkt Price is 0.3 Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.3 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -99% High stock price volatilityVol 12M is 575% Key risksCURX key risks include [1] uncertain clinical trial outcomes for its lead candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -48% |
| Weak multi-year price returns2Y Excs Rtn is -91%, 3Y Excs Rtn is -125% |
| Penny stockMkt Price is 0.3 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.3 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -99% |
| High stock price volatilityVol 12M is 575% |
| Key risksCURX key risks include [1] uncertain clinical trial outcomes for its lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 6/18/2026
Curanex Pharmaceuticals (CURX) stock has lost about 40% since 2/28/2026 because of the following key factors:
1. Nasdaq Minimum Bid Price Non-Compliance and Approved Reverse Stock Split.
Curanex Pharmaceuticals (CURX) faced non-compliance with Nasdaq's $1.00 minimum bid price requirement during the period, a significant factor for investor concern. The company was granted an extended compliance period through November 2, 2026, to regain compliance. To address this, the majority stockholders approved a reverse stock split at a ratio between 1-for-10 and 1-for-50 on June 11, 2026. Reverse stock splits are often viewed negatively by the market as they can signal financial distress and typically do not alter the underlying company valuation, instead reducing the number of outstanding shares and increasing the per-share price.
2. Widening Net Loss in Fiscal Q1 2026 Driven by Increased R&D.
For the fiscal quarter ended March 31, 2026 (fiscal Q1 2026), Curanex Pharmaceuticals reported a net loss of $3.15 million. This represents a substantial increase compared to a net loss of $0.14 million a year earlier. The widening loss was primarily attributed to increased operational expenses, with research and development (R&D) costs rising to $2.26 million and general and administrative (G&A) expenses reaching $0.93 million, as the company intensified efforts on its botanical drug pipeline. While increased R&D is common for a developmental-stage biotech, a sharp increase in losses without immediate clinical milestones can raise investor apprehension.
Show more
Curanex Pharmaceuticals (CURX) stock has lost about 40% since 2/28/2026 because of the following key factors:
1. Nasdaq Minimum Bid Price Non-Compliance and Approved Reverse Stock Split.
Curanex Pharmaceuticals (CURX) faced non-compliance with Nasdaq's $1.00 minimum bid price requirement during the period, a significant factor for investor concern. The company was granted an extended compliance period through November 2, 2026, to regain compliance. To address this, the majority stockholders approved a reverse stock split at a ratio between 1-for-10 and 1-for-50 on June 11, 2026. Reverse stock splits are often viewed negatively by the market as they can signal financial distress and typically do not alter the underlying company valuation, instead reducing the number of outstanding shares and increasing the per-share price.
2. Widening Net Loss in Fiscal Q1 2026 Driven by Increased R&D.
For the fiscal quarter ended March 31, 2026 (fiscal Q1 2026), Curanex Pharmaceuticals reported a net loss of $3.15 million. This represents a substantial increase compared to a net loss of $0.14 million a year earlier. The widening loss was primarily attributed to increased operational expenses, with research and development (R&D) costs rising to $2.26 million and general and administrative (G&A) expenses reaching $0.93 million, as the company intensified efforts on its botanical drug pipeline. While increased R&D is common for a developmental-stage biotech, a sharp increase in losses without immediate clinical milestones can raise investor apprehension.
Show more
Updated on 6/18/2026
Curanex Pharmaceuticals (CURX) stock has lost about 40% since 2/28/2026 because of the following key factors:
1. Nasdaq Minimum Bid Price Non-Compliance and Approved Reverse Stock Split.
Curanex Pharmaceuticals (CURX) faced non-compliance with Nasdaq's $1.00 minimum bid price requirement during the period, a significant factor for investor concern. The company was granted an extended compliance period through November 2, 2026, to regain compliance. To address this, the majority stockholders approved a reverse stock split at a ratio between 1-for-10 and 1-for-50 on June 11, 2026. Reverse stock splits are often viewed negatively by the market as they can signal financial distress and typically do not alter the underlying company valuation, instead reducing the number of outstanding shares and increasing the per-share price.
2. Widening Net Loss in Fiscal Q1 2026 Driven by Increased R&D.
For the fiscal quarter ended March 31, 2026 (fiscal Q1 2026), Curanex Pharmaceuticals reported a net loss of $3.15 million. This represents a substantial increase compared to a net loss of $0.14 million a year earlier. The widening loss was primarily attributed to increased operational expenses, with research and development (R&D) costs rising to $2.26 million and general and administrative (G&A) expenses reaching $0.93 million, as the company intensified efforts on its botanical drug pipeline. While increased R&D is common for a developmental-stage biotech, a sharp increase in losses without immediate clinical milestones can raise investor apprehension.
3. Early-Stage Pipeline Development with Associated High Risk and Limited Cash Runway.
Curanex Pharmaceuticals remains a developmental-stage company, with its lead candidate, Phyto-N, in preclinical and Investigational New Drug (IND)-enabling stages. Although the company announced the completion of GMP-compliant pilot production and favorable toxicology results for Phyto-N in fiscal Q1 2026 and targets an IND submission in fiscal Q4 2026, the drug has yet to enter clinical trials. This pre-clinical status inherently carries significant development risk. As of March 31, 2026, the company held approximately $4.0 million in cash and cash equivalents. While management believes this is sufficient for upcoming development activities for at least 12 months, the substantial Q1 2026 net loss of $3.15 million indicates a considerable cash burn rate, potentially raising concerns about future financing needs or dilution in a capital-intensive industry.
Show less
Curanex Pharmaceuticals (CURX) stock has lost about 40% since 2/28/2026 because of the following key factors:
1. Nasdaq Minimum Bid Price Non-Compliance and Approved Reverse Stock Split.
Curanex Pharmaceuticals (CURX) faced non-compliance with Nasdaq's $1.00 minimum bid price requirement during the period, a significant factor for investor concern. The company was granted an extended compliance period through November 2, 2026, to regain compliance. To address this, the majority stockholders approved a reverse stock split at a ratio between 1-for-10 and 1-for-50 on June 11, 2026. Reverse stock splits are often viewed negatively by the market as they can signal financial distress and typically do not alter the underlying company valuation, instead reducing the number of outstanding shares and increasing the per-share price.
2. Widening Net Loss in Fiscal Q1 2026 Driven by Increased R&D.
For the fiscal quarter ended March 31, 2026 (fiscal Q1 2026), Curanex Pharmaceuticals reported a net loss of $3.15 million. This represents a substantial increase compared to a net loss of $0.14 million a year earlier. The widening loss was primarily attributed to increased operational expenses, with research and development (R&D) costs rising to $2.26 million and general and administrative (G&A) expenses reaching $0.93 million, as the company intensified efforts on its botanical drug pipeline. While increased R&D is common for a developmental-stage biotech, a sharp increase in losses without immediate clinical milestones can raise investor apprehension.
3. Early-Stage Pipeline Development with Associated High Risk and Limited Cash Runway.
Curanex Pharmaceuticals remains a developmental-stage company, with its lead candidate, Phyto-N, in preclinical and Investigational New Drug (IND)-enabling stages. Although the company announced the completion of GMP-compliant pilot production and favorable toxicology results for Phyto-N in fiscal Q1 2026 and targets an IND submission in fiscal Q4 2026, the drug has yet to enter clinical trials. This pre-clinical status inherently carries significant development risk. As of March 31, 2026, the company held approximately $4.0 million in cash and cash equivalents. While management believes this is sufficient for upcoming development activities for at least 12 months, the substantial Q1 2026 net loss of $3.15 million indicates a considerable cash burn rate, potentially raising concerns about future financing needs or dilution in a capital-intensive industry.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -41.0% change in CURX stock from 2/28/2026 to 6/27/2026 was primarily driven by a -9.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282026 | 6272026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.45 | 0.27 | -41.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 26 | 28 | -9.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2026 to 6/27/2026| Return | Correlation | |
|---|---|---|
| CURX | -41.0% | |
| Market (SPY) | 6.6% | 13.0% |
| Sector (XLV) | 0.5% | 9.9% |
Fundamental Drivers
The -45.5% change in CURX stock from 11/30/2025 to 6/27/2026 was primarily driven by a -9.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 6272026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.49 | 0.27 | -45.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 26 | 28 | -9.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 6/27/2026| Return | Correlation | |
|---|---|---|
| CURX | -45.5% | |
| Market (SPY) | 7.3% | 8.4% |
| Sector (XLV) | 2.6% | 0.2% |
Fundamental Drivers
The -56.5% change in CURX stock from 5/31/2025 to 6/27/2026 was primarily driven by a -2.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312025 | 6272026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.61 | 0.27 | -56.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 28 | 28 | -2.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2025 to 6/27/2026| Return | Correlation | |
|---|---|---|
| CURX | -56.5% | |
| Market (SPY) | 25.1% | 10.8% |
| Sector (XLV) | 23.0% | 5.1% |
Fundamental Drivers
nullnull
Market Drivers
5/31/2023 to 6/27/2026| Return | Correlation | |
|---|---|---|
| CURX | -56.5% | |
| Market (SPY) | 81.3% | 10.8% |
| Sector (XLV) | 31.9% | 5.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CURX Return | 0% | 0% | 0% | 0% | -46% | -21% | -57% |
| Peers Return | 5% | -40% | -10% | 51% | 99% | 45% | 145% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 96% |
Monthly Win Rates [3] | |||||||
| CURX Win Rate | 0% | 0% | 0% | 0% | 8% | 33% | |
| Peers Win Rate | 56% | 44% | 50% | 52% | 60% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| CURX Max Drawdown | 0% | 0% | 0% | 0% | -96% | -51% | |
| Peers Max Drawdown | -44% | -62% | -59% | -37% | -43% | -27% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: KYMR, APGE, NKTR, ABBV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/26/2026 (YTD)
About Curanex Pharmaceuticals (CURX)
N/A
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Jun Liu Chief Executive Officer, Chairman of the Board and President
Jun Liu was appointed as President and Chairman of the Board of Curanex Pharmaceuticals Inc. in February 2024. In March 2026, a four-year executive employment agreement formalized his ongoing leadership, entrusting him with overall responsibility for the company's management, corporate strategy, research and development oversight, clinical and regulatory coordination, capital markets activities, and business execution. He directly owns 24.97% of the company's shares.
Wanjun Zhang Chief Financial Officer and Treasurer
Wanjun Zhang was appointed Chief Financial Officer and Treasurer of Curanex Pharmaceuticals Inc. effective January 1, 2026. He is 52 years old and brings over 20 years of experience in financial and accounting roles, with expertise in financial reporting, compliance, and business strategy. Prior to joining Curanex, Mr. Zhang provided financial consulting and accounting services to small and medium-sized companies since July 2020. He previously served as finance director at Beijing Huaxiahuitong Petty Loan Co. Ltd. from July 2017 to July 2020 and as finance director at Perfect World (Beijing) Software Co., Ltd., a former NASDAQ-listed company, from August 2010 to February 2016. Mr. Zhang holds a Bachelor's degree in Accounting from the Central University of Finance and Economics in Beijing, China.
Dr. Ning Zhang, PhD Chief Technology Officer
Dr. Ning Zhang holds the position of Chief Technology Officer at Curanex Pharmaceuticals.
Dr. Liqin Xie, PhD Chief Operating Officer
Dr. Liqin Xie serves as the Chief Operating Officer of Curanex Pharmaceuticals Inc. An at-will executive employment agreement for Dr. Xie became effective on March 1, 2026. She is involved in the operational aspects of the company's drug development, including milestones such as the completion of GMP-compliant pilot-scale batches for drug candidates.
Dr. Huijuan Zhong Chief Science Officer and Director
Dr. Huijuan Zhong is the Chief Science Officer and a Director at Curanex Pharmaceuticals.
AI Analysis | Feedback
The key risks for Curanex Pharmaceuticals (CURX) primarily stem from its status as a developmental-stage pharmaceutical company with no current revenue-generating products.
- Clinical Development and Regulatory Approval Risk: As a preclinical-stage pharmaceutical company, Curanex Pharmaceuticals' success is heavily reliant on the successful progression of its lead botanical drug candidate, Phyto-N, through rigorous preclinical studies, Investigational New Drug (IND) submission, and subsequent clinical trials. The company is currently targeting an IND submission for ulcerative colitis in the fourth quarter of 2026, with Phase I clinical trials expected to follow. Failures at any stage of development, delays in regulatory approvals, or unexpected adverse effects could significantly impede its ability to bring products to market, which is a common and critical risk for companies in this industry.
- Financial Sustainability and Cash Runway: Curanex Pharmaceuticals reported negative net income and no revenue in the past year, indicating a reliance on external funding for its operations. The company has a limited cash runway, less than one year, suggesting that it will need to secure additional financing in the near future to continue its drug development programs. While its current liquidity and solvency are excellent with no outstanding debt, this financial health is based on its recent initial public offering in August 2025, which raised $15 million. Sustaining operations and advancing drug candidates without a commercialized product poses a significant financial risk.
- High Stock Volatility and Low Liquidity: The company's stock is characterized by high volatility and is considered "very high risk" due to periodic low trading volume. Such volatility can lead to significant fluctuations in share price, making it a speculative investment. Low liquidity can also make it challenging for investors to buy or sell shares without significantly impacting the stock price.
AI Analysis | Feedback
null
AI Analysis | Feedback
Curanex Pharmaceuticals (CURX) Addressable Markets for Main Products and Services
Curanex Pharmaceuticals (CURX) is a developmental-stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is being developed for several indications, with ulcerative colitis being the primary focus.
The addressable markets for Curanex Pharmaceuticals' main product indications are as follows, with market sizes provided globally:
- Ulcerative Colitis: The global ulcerative colitis market size was valued at approximately USD 6.59 billion in 2024 and is projected to reach USD 9.72 billion by 2033. Other estimates place the global market at USD 8.3 billion in 2025, growing to USD 14.9 billion by 2035.
- Atopic Dermatitis: The global atopic dermatitis drugs market size was valued at approximately USD 12.1 billion in 2024 and is estimated to grow to USD 31 billion by 2034.
- Type 2 Diabetes: The global Type 2 Diabetes market size was valued at approximately USD 36.7 billion in 2024 and is projected to reach USD 71.55 billion by 2033.
- Nonalcoholic Fatty Liver Disease (NAFLD): The global NAFLD drug market size is estimated to be around USD 21.98 billion in 2025 and is predicted to increase to approximately USD 33.6 billion by 2034.
- Gout: The global gout treatment market size was valued at approximately USD 2.40 billion in 2024 and is expected to reach USD 4.75 billion by 2032. Another report estimates the global gout therapeutics market at USD 3.0 billion in 2025, growing to USD 5.7 billion by 2035.
AI Analysis | Feedback
Curanex Pharmaceuticals (CURX) is a developmental-stage biotechnology company focused on discovering, developing, and commercializing botanical drugs for inflammatory diseases. The company's future revenue growth over the next 2-3 years is primarily anticipated to be driven by progress in its lead drug candidate and strategic advancements in its pipeline.
Here are 3-5 expected drivers of future revenue growth for Curanex Pharmaceuticals:
- Advancement of Phyto-N for Ulcerative Colitis: Curanex's lead botanical drug candidate, Phyto-N, is primarily focused on treating moderate to severe ulcerative colitis. The company has recently completed a Good Manufacturing Practice (GMP)-compliant pilot-scale batch of Phyto-N. Curanex plans to submit an Investigational New Drug (IND) application for ulcerative colitis and initiate Phase I clinical trials in the fourth quarter of 2026. Successful progression through these regulatory and clinical milestones will be a critical driver for future revenue potential.
- Expansion into Multiple Therapeutic Indications for Phyto-N: Beyond ulcerative colitis, Phyto-N is in preclinical research for several other inflammatory conditions, including atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD), and gout. Advancing Phyto-N through development for these additional indications would significantly broaden the drug's market potential and open new avenues for revenue generation.
- Strategic Licensing Agreements and Commercialization: As a developmental-stage company, Curanex Pharmaceuticals anticipates revenue generation only upon successful commercialization of its products or through strategic licensing agreements. Future partnerships or licensing deals with larger pharmaceutical entities for Phyto-N or other pipeline candidates could provide crucial funding, milestone payments, and eventual royalties, thereby driving revenue growth.
- Leveraging Botanical Drug Development Approach: Curanex emphasizes its unique botanical drug development approach, which aims for high-efficacy botanical drugs with de-risked clinical pathways. The company highlights that Phyto-N has a history of human use over 30 years in China, demonstrating favorable tolerability and providing extensive preclinical data across multiple indications. This established safety profile and scientific backing for its botanical programs could expedite regulatory approvals and market acceptance, serving as a competitive advantage and a driver for accelerated commercialization.
AI Analysis | Feedback
Share Issuance
- Curanex Pharmaceuticals completed its Initial Public Offering (IPO) in August 2025, issuing 3.75 million shares of common stock at $4.00 per share, generating gross proceeds of $15 million.
- The underwriters fully exercised their over-allotment option in September 2025, purchasing an additional 562,500 shares at $4.00 each, resulting in an additional $2.25 million in gross proceeds and bringing the total gross proceeds from the IPO to $17.25 million.
- The company issued 28,312 shares of its common stock to an investor for $200,000 in a private placement in September 2025.
Inbound Investments
- The company received $200,000 from investor Xiaohong Song through a private placement of common stock in September 2025.
- Curanex Pharmaceuticals received loans totaling $400,000 from Dian Ying Jing, the company's secretary and spouse of the chief executive officer, in February and May 2025, which were subsequently repaid in September 2025.
Capital Expenditures
- Net proceeds from the August 2025 IPO, approximately $12.87 million, are intended to fund the development of its lead product candidate, Phyto-N, for ulcerative colitis, including FDA-required toxicology and pharmacokinetic studies, and preparation of an Investigational New Drug (IND) application.
- As of September 30, 2025, Curanex reported $8.47 million in prepaid research and development with Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs).
- In February 2026, Curanex completed a Good Manufacturing Practice (GMP)-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N, a key manufacturing milestone supporting upcoming toxicology and pharmacokinetic studies for a planned IND submission in Q4 2026.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 108.12 |
| Mkt Cap | 9.2 |
| Rev LTM | 51 |
| Op Inc LTM | -125 |
| FCF LTM | -204 |
| FCF 3Y Avg | -183 |
| CFO LTM | -204 |
| CFO 3Y Avg | -181 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -12.6% |
| Rev Chg 3Y Avg | 3.6% |
| Rev Chg Q | 12.4% |
| QoQ Delta Rev Chg LTM | 2.7% |
| Op Inc Chg LTM | -26.3% |
| Op Inc Chg 3Y Avg | -11.1% |
| Op Mgn LTM | -224.1% |
| Op Mgn 3Y Avg | -177.2% |
| QoQ Delta Op Mgn LTM | 12.7% |
| CFO/Rev LTM | -366.3% |
| CFO/Rev 3Y Avg | -259.4% |
| FCF/Rev LTM | -366.6% |
| FCF/Rev 3Y Avg | -260.2% |
Price Behavior
Price Behavior
| Market Price | $0.27 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/11/2010 | |
| Distance from 52W High | -97.1% | |
| 50 Days | 200 Days | |
| DMA Price | $2.14 | $2.14 |
| DMA Trend | down | down |
| Distance from DMA | -87.6% | -87.6% |
| 3M | 1YR | |
| Volatility | 80.6% | 143.8% |
| Downside Capture | 144.28 | 470.72 |
| Upside Capture | -132.88 | 7.33 |
| Correlation (SPY) | 20.8% | 5.2% |
CURX Betas & Captures as of 5/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.64 | 1.52 | 0.79 | 0.70 | 2.37 | 0.50 |
| Up Beta | 4.10 | 3.61 | 2.89 | 1.54 | -1.96 | -0.38 |
| Down Beta | 3.61 | 3.27 | 1.94 | 0.41 | -0.04 | -0.12 |
| Up Capture | -146% | -126% | -75% | 3% | 507% | 47% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 8 | 17 | 28 | 53 | 83 | 83 |
| Down Capture | 338% | 230% | 23% | 119% | 210% | 106% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 12 | 24 | 35 | 71 | 107 | 107 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CURX | |
|---|---|---|---|---|
| CURX | -93.5% | 143.8% | -1.09 | - |
| Sector ETF (XLV) | 21.4% | 15.4% | 1.06 | 5.1% |
| Equity (SPY) | 21.2% | 12.4% | 1.26 | 10.8% |
| Gold (GLD) | 21.8% | 27.7% | 0.70 | 5.7% |
| Commodities (DBC) | 21.8% | 18.6% | 0.92 | 6.7% |
| Real Estate (VNQ) | 16.1% | 13.6% | 0.85 | 8.3% |
| Bitcoin (BTCUSD) | -44.2% | 42.5% | -1.25 | 15.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CURX | |
|---|---|---|---|---|
| CURX | -42.0% | 143.8% | -1.09 | - |
| Sector ETF (XLV) | 7.0% | 14.8% | 0.29 | 5.1% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 10.8% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | 5.7% |
| Commodities (DBC) | 7.4% | 19.5% | 0.28 | 6.7% |
| Real Estate (VNQ) | 3.4% | 18.9% | 0.08 | 8.3% |
| Bitcoin (BTCUSD) | 10.9% | 54.0% | 0.39 | 15.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CURX | |
|---|---|---|---|---|
| CURX | -23.8% | 143.8% | -1.09 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.51 | 5.1% |
| Equity (SPY) | 15.2% | 18.0% | 0.72 | 10.8% |
| Gold (GLD) | 11.8% | 16.1% | 0.60 | 5.7% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | 6.7% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 8.3% |
| Bitcoin (BTCUSD) | 54.7% | 66.4% | 0.95 | 15.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/27/2026